Piroxicam
Piroxicam is a non-selective COX inhibitor. (In Vitro) :Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells. (In Vivo) :Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration.
Product Specifications
CAS Number
36322-90-4
Product Name Alternative
Feldene | Larapam | NSC 666076
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Ethanol: 1 mg/mL (3.01 mM) ; DMSO: 66 mg/mL (199.18 mM)
Smiles
CN1C (=C (C2=CC=CC=C2S1 (=O) =O) O) C (=O) NC3=CC=CC=N3
Molecular Formula
C15H13N3O4S
Molecular Weight
331.35
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
